Serotonin Syndrome

Quick Answer

Serotonin syndrome is a potentially life-threatening drug-induced toxidrome resulting from excess serotonergic activity at central and peripheral serotonin receptors. It is characterised by a clinical triad of neuromuscular excitation (clonus, hyperreflexia, rigidity), autonomic dysfunction (hyperthermia, diaphoresis, tachycardia), and altered mental status (agitation, confusion). Diagnosis is clinical using the Hunter Serotonin Toxicity Criteria, which requires a serotonergic agent plus specific clinical features, with clonus (spontaneous, inducible, or ocular) being the most diagnostically important finding. [1,2]

Key Management Principles:

1. Remove precipitating agents immediately (cease all serotonergic drugs)
2. Supportive care: IV fluids, active cooling for hyperthermia greater than 39.5 degrees Celsius
3. Benzodiazepines (diazepam 5-10 mg IV or midazolam 5-10 mg IV): First-line for agitation, tremor, and myoclonus
4. Cyproheptadine (5-HT2A antagonist): Loading dose 12 mg orally/NG, then 2 mg every 2 hours (max 32 mg/day)
5. Intubation and paralysis (non-depolarising agents): For severe hyperthermia greater than 41.1 degrees Celsius or refractory agitation
6. Avoid suxamethonium: Risk of hyperkalaemia from rhabdomyolysis [3,4,5]

Most cases resolve within 24-72 hours of precipitant removal with supportive care. Mortality occurs primarily from severe hyperthermia with multi-organ failure, rhabdomyolysis, DIC, and ARDS. [6,7]

---

CICM Exam Focus

Written Exam High-Yield Topics

1. Hunter Serotonin Toxicity Criteria: Validated diagnostic algorithm requiring serotonergic agent PLUS specific clinical findings (clonus most important)
2. Serotonin syndrome vs NMS comparison: Key differentiating features (onset, muscle tone, clonus, reflexes, pupil size)
3. Causative drug classes: SSRIs, SNRIs, MAOIs, TCAs, opioids (tramadol, fentanyl, pethidine), linezolid, ondansetron
4. Most dangerous combination: MAOIs + SSRIs/serotonergic drugs (can be fatal)
5. Cyproheptadine mechanism and dosing: 5-HT2A receptor antagonist; loading 12 mg, maintenance 2 mg q2h
6. Benzodiazepines rationale: Control muscle hyperactivity, reduce heat generation, treat agitation
7. Why to avoid suxamethonium: Hyperkalaemia risk from rhabdomyolysis-induced muscle breakdown

Viva Voce Themes

• Pathophysiology of serotonin excess at synaptic cleft and receptor subtypes involved (5-HT1A, 5-HT2A)
• Clinical approach to differentiating serotonin syndrome from NMS (key is clonus and hyperreflexia vs rigidity and bradyreflexia)
• Management algorithm for mild, moderate, and severe serotonin syndrome
• Drug interactions leading to serotonin syndrome (case-based scenarios)
• Role of paralysis in severe hyperthermia and why it masks clinical signs (clonus disappears)
• Evidence for cyproheptadine (limited to case series; no RCT data)

Common SAQ Stems

• "A 45-year-old woman presents with agitation, tremor, and fever 6 hours after starting a new medication in addition to her usual sertraline..."
• "Compare and contrast the clinical features and management of serotonin syndrome and neuroleptic malignant syndrome..."
• "A patient on tranylcypromine presents confused after taking over-the-counter cold medication containing dextromethorphan..."

Common Pitfalls

• Confusing serotonin syndrome with NMS: Serotonin syndrome has CLONUS and HYPERREFLEXIA; NMS has RIGIDITY and BRADYREFLEXIA
• Misdiagnosis due to atypical presentation: Mild cases may only show tremor, akathisia, diaphoresis
• Using suxamethonium for intubation: Contraindicated due to rhabdomyolysis risk and hyperkalaemia
• Failing to recognise non-psychiatric serotonergic drugs: Linezolid (antibiotic), ondansetron (antiemetic), tramadol/fentanyl/pethidine (analgesics)
• Not checking wash-out periods: MAOIs require 2-5 weeks washout before starting serotonergic drugs
• Over-reliance on serum serotonin levels: Not clinically useful; diagnosis is purely clinical
• Forgetting that paralysis masks clonus: Clinical monitoring becomes unreliable after paralysis

---

Key Points

• Serotonin syndrome is a drug-induced toxidrome from excess 5-HT at central and peripheral receptors, NOT an idiosyncratic reaction [1,2]
• Onset is rapid: Usually within 6-24 hours of precipitant exposure (contrast with NMS: days to weeks) [6,8]
• Hunter Criteria is the validated diagnostic tool: Sensitivity 84%, specificity 97% for moderate-severe cases [9]
• Clonus is the key finding: Spontaneous, inducible, or ocular clonus distinguishes serotonin syndrome from other hyperthermic syndromes [2,9]
• Most dangerous interaction: MAOI + SSRI/SNRI (mortality up to 10-15%) [10,11]
• Opioids causing serotonin syndrome: Tramadol (most common), fentanyl, pethidine, methadone, tapentadol; morphine and oxycodone are safe [12,13]
• Management priorities: Stop serotonergic drugs, benzodiazepines for agitation, cyproheptadine for moderate-severe, paralysis and cooling for severe hyperthermia [3,4,5]
• Cyproheptadine dosing: 12 mg loading (oral/NG), then 2 mg every 2 hours; maximum 32 mg/day [14,15]
• Paralysis indication: Temperature greater than 41.1 degrees Celsius, severe rigidity, refractory agitation; use non-depolarising agents (rocuronium) [3,16]
• Prognosis is excellent with early recognition: 70% resolve within 24 hours, most within 72 hours [6,7]

---

Applied Basic Sciences

Serotonin Biochemistry

Serotonin Synthesis:

Serotonin (5-hydroxytryptamine, 5-HT) is synthesised from the essential amino acid L-tryptophan in a two-step process: [17,18]

L-Tryptophan
     ↓ Tryptophan hydroxylase (TPH) [Rate-limiting step]
5-Hydroxytryptophan (5-HTP)
     ↓ Aromatic L-amino acid decarboxylase (AADC)
5-Hydroxytryptamine (Serotonin, 5-HT)

Distribution:

• Central nervous system (2%): Raphe nuclei of brainstem (primary source of CNS 5-HT)
• Peripheral tissues (98%): Enterochromaffin cells of GI tract (95%), platelets (via uptake), mast cells

Serotonin Metabolism:

Serotonin (5-HT)
     ↓ Monoamine oxidase A (MAO-A)
5-Hydroxyindoleacetaldehyde
     ↓ Aldehyde dehydrogenase
5-Hydroxyindoleacetic acid (5-HIAA) [Excreted in urine]

Key Enzymes:

• Tryptophan hydroxylase (TPH): Rate-limiting enzyme; TPH1 (peripheral), TPH2 (CNS)
• Monoamine oxidase A (MAO-A): Primary degradation enzyme; inhibited by MAOIs
• Monoamine oxidase B (MAO-B): Primarily degrades dopamine; selegiline at low doses is selective [17,18]

Serotonin Receptors

There are 7 families of serotonin receptors (5-HT1 through 5-HT7) with at least 14 subtypes. The receptors most relevant to serotonin syndrome are: [19,20,21]

5-HT2A Receptor: The Key Mediator

The 5-HT2A receptor is the primary mediator of serotonin syndrome toxicity: [20,21,22]

• Located on cortical pyramidal neurons, brainstem motoneurons, and spinal cord interneurons
• Activation causes: hyperthermia, muscle hyperactivity (clonus, myoclonus, rigidity), agitation
• Cyproheptadine is an antagonist at this receptor, explaining its therapeutic effect
• Haloperidol also has 5-HT2A antagonism but D2 blockade may worsen hyperthermia

Mechanism of Toxicity

Serotonin syndrome results from excess serotonergic activity at central nervous system synapses, particularly at 5-HT2A receptors in the brainstem and spinal cord. [1,2,22]

Mechanisms of Increased Synaptic Serotonin:

The Serotonin Synapse in Toxicity:

                     PRESYNAPTIC NEURON
                            │
                    [Tryptophan]
                            ↓
                      [5-HT synthesis]
                            ↓
           ┌─── [5-HT vesicles] ◄──── Amphetamines/MDMA (↑ release)
           │           │
           │           ↓ (Exocytosis)
           │    ╔══════════════════╗
           │    ║   SYNAPTIC CLEFT ║
           │    ║   [5-HT] ↑↑↑     ║ ◄──── MAOIs (↓ degradation)
           │    ╚══════════════════╝
           │           │
           │           ↓
           │    [5-HT receptors] ──── Buspirone/Triptans (direct agonism)
           │           │
           │    POSTSYNAPTIC NEURON
           │           │
           │           └──→ 5-HT2A activation → SEROTONIN SYNDROME
           │
           └───► [SERT reuptake] ◄───── SSRIs/SNRIs/TCAs/Tramadol (↓ reuptake)

CNS vs Peripheral Serotonin Effects

Central Nervous System Effects (Toxicity):

• Hyperthermia (hypothalamic thermoregulation disruption)
• Agitation, delirium, coma
• Myoclonus, hyperreflexia, clonus (spinal cord hyperexcitability)
• Rigidity (severe cases)
• Seizures (rare)

Peripheral Effects:

• Diarrhoea, nausea, vomiting (5-HT3 receptors in GI tract)
• Vasoconstriction (5-HT2A receptors on vascular smooth muscle)
• Platelet aggregation (5-HT2A receptors on platelets)
• Diaphoresis (autonomic activation)

Hyperthermia Mechanisms

Hyperthermia in serotonin syndrome is multifactorial: [23,24,25]

1. Central thermoregulatory failure: 5-HT2A activation in hypothalamus raises temperature set-point
2. Excessive muscle activity: Myoclonus, clonus, rigidity generate metabolic heat
3. Increased metabolic rate: Sympathetic activation, agitation
4. Impaired heat dissipation: Peripheral vasoconstriction (5-HT2A mediated)
5. Uncoupling of oxidative phosphorylation: Proposed mechanism in severe cases

Temperature Thresholds:

• Mild: 37-38.5 degrees Celsius
• Moderate: 38.5-40 degrees Celsius
• Severe: greater than 40 degrees Celsius (life-threatening)
• Critical: greater than 41.1 degrees Celsius (requires paralysis)

---

Causative Agents

Classification by Mechanism

Serotonin Reuptake Inhibitors:

Monoamine Oxidase Inhibitors:

Serotonin Releasers:

Direct Receptor Agonists:

Other Serotonergic Agents:

High-Risk Drug Combinations

Most Dangerous Combinations (Contraindicated):

Required Washout Periods Before Starting MAOIs:

After Stopping MAOIs:

• Irreversible MAOIs (phenelzine, tranylcypromine): Wait 2-3 weeks (14-21 days) before starting serotonergic drugs
• Reversible MAOIs (moclobemide): Wait 24-48 hours
• Linezolid: Wait 24 hours after last dose [26,27]

Opioid Serotonergic Risk Stratification

Opioids with Significant Serotonergic Activity:

Opioids Considered Safe (No Significant SERT Inhibition):

• Morphine
• Oxycodone
• Hydromorphone
• Codeine
• Buprenorphine

Australian Clinical Relevance:

• Tramadol is commonly prescribed and available without S8 scheduling in some formulations
• Pethidine use is declining due to toxicity concerns
• Patients on MAOIs requiring analgesia: Use morphine, oxycodone, or hydromorphone [12,13]

---

Clinical Presentation

Hunter Serotonin Toxicity Criteria

The Hunter Serotonin Toxicity Criteria (HSTC) is the validated diagnostic tool for serotonin syndrome, with sensitivity of 84% and specificity of 97% for moderate-to-severe cases. It requires: [9]

Prerequisite: Recent exposure to a serotonergic agent

PLUS any ONE of the following:

                        ┌─────────────────────────────────────┐
                        │  SEROTONERGIC AGENT EXPOSURE        │
                        │  (within 5 half-lives of last dose) │
                        └─────────────────────────────────────┘
                                        │
              ┌─────────────────────────┼─────────────────────────┐
              │                         │                         │
              ▼                         ▼                         ▼
    ┌─────────────────┐     ┌─────────────────┐     ┌─────────────────┐
    │ SPONTANEOUS     │     │ INDUCIBLE       │     │ OCULAR CLONUS   │
    │ CLONUS          │     │ CLONUS          │     │ PLUS            │
    │                 │     │ PLUS            │     │ (Agitation OR   │
    │                 │     │ (Agitation OR   │     │ Diaphoresis)    │
    │                 │     │ Diaphoresis)    │     │                 │
    └─────────────────┘     └─────────────────┘     └─────────────────┘
              │                         │                         │
              └─────────────────────────┼─────────────────────────┘
                                        │
                                        ▼
                        ┌─────────────────────────────────────┐
                        │       = SEROTONIN SYNDROME          │
                        └─────────────────────────────────────┘

Alternative Criteria (if no clonus present):

    ┌─────────────────────────────────────────────────────────────┐
    │  TREMOR + HYPERREFLEXIA                                     │
    │  PLUS                                                       │
    │  (Inducible clonus OR Ocular clonus OR Spontaneous clonus) │
    └─────────────────────────────────────────────────────────────┘
                                  │
                                  ▼
                   ┌─────────────────────────────────────┐
                   │       = SEROTONIN SYNDROME          │
                   └─────────────────────────────────────┘

OR:

    ┌─────────────────────────────────────────────────────────────┐
    │  HYPERTONIA + TEMPERATURE > 38°C + OCULAR CLONUS            │
    │  OR                                                         │
    │  HYPERTONIA + TEMPERATURE > 38°C + INDUCIBLE CLONUS         │
    └─────────────────────────────────────────────────────────────┘
                                  │
                                  ▼
                   ┌─────────────────────────────────────┐
                   │       = SEROTONIN SYNDROME          │
                   └─────────────────────────────────────┘

Clinical Features by System

Neuromuscular Findings (Most Diagnostically Important):

Key Point: Clonus is present in serotonin syndrome but ABSENT in NMS. Rigidity in serotonin syndrome is typically less severe than in NMS and often affects lower greater than upper limbs.

Autonomic Features:

Mental Status Changes:

Severity Classification

Mild Serotonin Syndrome:

• Tremor, hyperreflexia, diaphoresis
• Mild tachycardia (HR less than 120 bpm)
• Temperature less than 38.5 degrees Celsius
• Anxiety, mild agitation
• Mydriasis
• Normal mental status or mild anxiety
• Management: Stop serotonergic agents, supportive care, observation 6-12 hours

Moderate Serotonin Syndrome:

• Above features PLUS:
• Inducible or spontaneous clonus
• Ocular clonus
• Temperature 38.5-40 degrees Celsius
• Tachycardia (HR 120-160 bpm)
• Hypertension or labile BP
• Agitation, confusion
• Management: Benzodiazepines, cyproheptadine, ICU admission

Severe/Life-Threatening Serotonin Syndrome:

• Temperature greater than 41 degrees Celsius (medical emergency)
• Severe muscle rigidity
• Metabolic acidosis
• Rhabdomyolysis (CK greater than 10,000 U/L)
• Renal failure
• DIC
• ARDS
• Seizures
• Coma
• Cardiovascular collapse
• Management: Intubation, paralysis with non-depolarising agents, aggressive cooling, ICU [6,7,28]

Time Course

Characteristic Onset:

• Rapid onset: 50% of cases within 2 hours, 60% within 6 hours, greater than 90% within 24 hours of precipitant exposure [6,8]
• Contrast with NMS: Days to weeks after neuroleptic initiation/dose change
• Precipitant types:
  • "New serotonergic drug started: 6-24 hours"
  • "Drug interaction (added second agent): 2-24 hours"
  • "Dose increase: 6-24 hours"
  • "Overdose: 1-6 hours"

Resolution:

• With precipitant removal: 70% resolve within 24 hours, most within 72 hours [6,7]
• Half-life dependent: Longer-acting agents (fluoxetine) may have prolonged course
• MAOI involvement: May be prolonged (1-2 weeks) due to irreversible enzyme inhibition

---

Differential Diagnosis

Serotonin Syndrome vs Neuroleptic Malignant Syndrome

This comparison is a CICM exam favourite. Understanding the key differences is essential for accurate diagnosis and appropriate management. [29,30,31]

Key Clinical Pearl: "If there is CLONUS, think SEROTONIN; if there is RIGIDITY without clonus, think NMS."

Comprehensive Differential Diagnosis Table

Distinguishing Serotonin Syndrome from Anticholinergic Toxidrome

"Wet vs Dry" Mnemonic:

Clinical Pearl: "Serotonin syndrome is wet and bouncy (sweaty with clonus); anticholinergic is dry and still (dry skin, no clonus)."

---

Investigations

Initial Assessment

Blood Tests:

Specific Toxicology:

Cardiac Monitoring:

Imaging:

Laboratory Findings in Severe Cases

Rhabdomyolysis Markers:

• CK greater than 5,000 U/L (severe: greater than 10,000 U/L)
• Myoglobinuria (dark urine)
• Hyperkalaemia
• Hyperphosphataemia
• Hypocalcaemia
• Acute kidney injury (raised creatinine)

DIC Markers:

• Prolonged PT/INR, APTT
• Thrombocytopenia
• Elevated D-dimer
• Low fibrinogen
• Schistocytes on blood film

Multi-Organ Failure:

• Elevated lactate (greater than 4 mmol/L)
• Elevated liver enzymes
• Raised creatinine
• Hypoxaemia (ARDS)
• Metabolic acidosis

---

ICU Management

General Principles

Treatment priorities (in order):

1. Cease all serotonergic agents immediately
2. Supportive care: Airway, breathing, circulation, temperature control
3. Benzodiazepines: Control agitation, reduce muscle hyperactivity
4. Cyproheptadine: Specific 5-HT2A antagonist for moderate-severe cases
5. Active cooling: For temperature greater than 39.5 degrees Celsius
6. Paralysis and intubation: For refractory hyperthermia or agitation
7. Treat complications: Rhabdomyolysis, DIC, multi-organ failure [3,4,5,14]

Immediate Resuscitation

Airway and Breathing:

• Secure airway early if GCS less than 8, refractory agitation, respiratory failure, or severe hyperthermia
• Avoid suxamethonium (hyperkalaemia risk from rhabdomyolysis)
• Use rocuronium 1-1.2 mg/kg for RSI
• Sugammadex available for reversal if needed
• Ventilate to normocapnia; avoid hyperventilation (may worsen seizures)

Circulation:

• IV access (large-bore, two sites)
• Aggressive IV fluid resuscitation (crystalloid; target urine output greater than 1-2 mL/kg/hr for rhabdomyolysis)
• Continuous cardiac monitoring
• Treat hypotension with fluids first, then vasopressors if needed
• Avoid direct-acting sympathomimetics in mild-moderate cases (may worsen hypertension)

Temperature:

• Continuous core temperature monitoring (oesophageal, bladder, or rectal probe)
• Active cooling if temperature greater than 39.5 degrees Celsius

Benzodiazepine Therapy

First-line treatment for:

• Agitation
• Tremor
• Myoclonus
• Rigidity (mild-moderate)
• Seizures
• Reducing metabolic heat generation

Dosing:

Rationale:

• GABA-A receptor agonism counteracts central excitation
• Reduces muscle hyperactivity → reduces heat generation
• Controls agitation without exacerbating syndrome
• Safe in combination with cyproheptadine [3,4,32]

Cyproheptadine

Mechanism:

• First-generation antihistamine with potent 5-HT2A receptor antagonism
• Blocks the receptor primarily responsible for serotonin syndrome toxicity [14,15,33]

Indications:

• Moderate-to-severe serotonin syndrome
• Inadequate response to benzodiazepines alone
• Adjunct in all cases with significant neuromuscular features

Dosing Protocol:

Practical Considerations:

• Only available in oral/NG formulation (no IV preparation)
• May cause sedation (antihistamine effect)
• May cause anticholinergic effects (dry mouth, urinary retention) at high doses
• Tablets can be crushed for NG administration
• Continue until 24 hours after symptom resolution [14,15]

Evidence:

• No randomised controlled trials exist
• Evidence limited to case series and case reports
• Widely recommended in guidelines based on pharmacological rationale and clinical experience [33,34]

Active Cooling

Indications:

• Core temperature greater than 39.5 degrees Celsius
• Refractory hyperthermia despite benzodiazepines and cyproheptadine

Methods:

Target:

• Core temperature less than 39 degrees Celsius
• Avoid hypothermia (less than 36 degrees Celsius)
• Cease active cooling when temperature 38-38.5 degrees Celsius (overshoot prevention)

Avoid antipyretics (paracetamol, NSAIDs): Ineffective as hyperthermia is from excessive muscle activity, not prostaglandin-mediated fever. [23,24]

Paralysis and Intubation

Indications for Neuromuscular Blockade:

• Core temperature greater than 41.1 degrees Celsius despite benzodiazepines and cooling
• Refractory rigidity preventing adequate ventilation
• Severe agitation not controlled by benzodiazepines
• Rhabdomyolysis with ongoing muscle hyperactivity

Key Principles:

1. Use non-depolarising neuromuscular blocking agents:

   • Rocuronium 0.6-1.2 mg/kg (preferred)
   • Vecuronium or cisatracurium as alternatives

2. AVOID suxamethonium:

   • Rhabdomyolysis causes muscle membrane instability
   • Risk of severe hyperkalaemia and cardiac arrest
   • Contraindicated in any patient with suspected rhabdomyolysis [3,16,35]

3. Remember that paralysis masks clinical signs:

   • Clonus will disappear
   • Hyperreflexia cannot be assessed
   • Monitor temperature, CK, lactate as surrogate markers
   • Continue cyproheptadine and benzodiazepines (sedation)

4. Sedation during paralysis:

   • Use propofol infusion or benzodiazepines
   • Ensure adequate sedation before paralysis
   • Use BIS monitoring if available

Ventilation Settings:

• Lung-protective ventilation if ARDS develops
• Target normocapnia (PaCO2 35-45 mmHg)
• Avoid hyperventilation

Management of Complications

Rhabdomyolysis:

• Aggressive IV crystalloid (target urine output greater than 2-3 mL/kg/hr)
• Monitor CK every 6-12 hours
• Treat hyperkalaemia aggressively (calcium gluconate, insulin/dextrose, salbutamol)
• Consider RRT if oliguric AKI despite resuscitation
• Avoid nephrotoxins (NSAIDs, aminoglycosides, contrast)
• Urinary alkalinisation (controversial; not routinely recommended) [36,37]

Acute Kidney Injury:

• Maintain euvolaemia
• Avoid nephrotoxins
• RRT if: severe acidosis, refractory hyperkalaemia, volume overload, uraemic complications
• CRRT preferred if haemodynamically unstable

Disseminated Intravascular Coagulation:

• Supportive care
• Treat underlying cause (remove precipitants, control hyperthermia)
• Blood products as clinically indicated (FFP, platelets, cryoprecipitate)

Seizures:

• Benzodiazepines first-line (lorazepam 4 mg IV or midazolam 10 mg IV/IM)
• Avoid phenytoin (sodium channel blockade may worsen)
• Levetiracetam as second-line if refractory
• Propofol or barbiturate infusion for status epilepticus [38]

ARDS:

• Lung-protective ventilation (6 mL/kg IBW, plateau pressure less than 30 cmH2O)
• PEEP titration
• Prone positioning if P/F ratio less than 150 mmHg
• Consider neuromuscular blockade (already indicated for temperature control)

What to Avoid

Drugs to AVOID in Serotonin Syndrome:

Dantrolene in Serotonin Syndrome:

• NOT first-line (mechanism is peripheral muscle relaxation, does not address central 5-HT toxicity)
• May be considered if temperature refractory despite paralysis, cooling, and cyproheptadine
• Theoretical benefit in reducing muscle-generated heat
• Limited case report evidence only
• Standard dosing if used: 1-2.5 mg/kg IV every 5-10 minutes (max 10 mg/kg) [39,40]

---

Australian/NZ Context

ANZICS-CORE and CICM Guidelines

• ANZICS-CORE does not have specific serotonin syndrome guidelines
• Management follows general toxicology principles and international consensus [41]
• Therapeutic Guidelines Australia (eTG Complete) provides recommendations for psychiatric drug toxicity [42]

Australian Poison Information Centres

National Poisons Information Centre (NPIC): 13 11 26 (24-hour service)

• Available for clinician consultation on complex drug interactions
• Can advise on serotonergic drug combinations
• Coordinate with toxicology services

State Toxicology Units:

• NSW Poisons Information Centre (Westmead)
• Victorian Poisons Information Centre (Austin Health)
• Queensland Poisons Information Centre (Lady Cilento)

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

• Higher rates of mental health disorders and antidepressant prescribing in some communities [43]
• Polypharmacy concerns: Multiple prescribers (GP, mental health, hospital) may not communicate
• Access barriers: Remote communities may have limited medication reconciliation systems
• Cultural considerations: Involve Aboriginal Health Workers (AHW) and Aboriginal Liaison Officers (ALO) in communication
• Health literacy: Ensure clear communication about drug interactions
• Traditional medicines: Some bush medicines may have serotonergic properties (limited data)
• Family involvement: Decision-making often involves extended family/community

Māori Health (New Zealand):

• Whānau-inclusive care: Involve family in discussions about medications and treatment
• Māori Health Workers: Engage in culturally safe communication
• Treaty of Waitangi principles: Partnership, participation, protection
• Higher rates of mental health burden: Consider social determinants

Practical Recommendations:

1. Medication reconciliation: Review ALL medications including traditional/complementary medicines
2. Culturally safe communication: Use interpreters, AHW/ALO, whānau involvement
3. Clear discharge information: Written and verbal instructions about drug interactions
4. Follow-up: Ensure continuity with community mental health services
5. Telehealth: Utilise for specialist consultation in remote areas

Retrieval Medicine Considerations

Rural and Remote Transfer:

• Stabilise before transfer (benzodiazepines, cyproheptadine)
• Ensure temperature control during transport
• Communicate drug history to receiving hospital
• RFDS/aeromedical services: Altitude considerations (may worsen hypoxia if ARDS)
• Telehealth consultation with toxicology services [44]

---

Prognosis and Outcomes

Natural History

With appropriate treatment:

• 70% resolve within 24 hours of precipitant removal
• Most cases resolve within 72 hours
• Complete recovery expected if treated early
• No long-term sequelae in most cases [6,7]

Duration depends on:

• Half-life of causative agent (fluoxetine: 4-6 days vs paroxetine: 21 hours)
• MAOIs: Irreversible inhibition takes 2-3 weeks to regenerate enzyme
• Severity of initial presentation
• Delay in diagnosis and treatment

Mortality and Morbidity

Mortality:

• Overall mortality: 2-12% (varies by series)
• Highest mortality: MAOI + SSRI combinations (10-15%)
• Deaths primarily from: Severe hyperthermia, ARDS, DIC, multi-organ failure, rhabdomyolysis
• Most deaths occur in first 24-48 hours [6,7,45]

Risk factors for death:

• Delay in diagnosis and treatment
• Temperature greater than 41 degrees Celsius
• MAOI involvement
• Severe metabolic acidosis (pH less than 7.1)
• CK greater than 10,000 U/L
• Multi-organ failure
• Pre-existing cardiovascular disease

Morbidity:

• Rhabdomyolysis with AKI (may require temporary dialysis)
• Hypoxic brain injury (if prolonged hyperthermia/hypoxia)
• ARDS requiring prolonged ventilation
• DIC with bleeding complications
• Most survivors have complete recovery

Prevention

Medication safety principles:

1. Careful prescribing: Review medication list before adding serotonergic drugs
2. Drug interaction databases: Use electronic prescribing systems with interaction alerts
3. Patient education: Warn about adding OTC medications (dextromethorphan, St John's wort)
4. MAOI washout: Ensure appropriate washout periods (2 weeks for most drugs, 5 weeks for fluoxetine)
5. Linezolid/methylene blue awareness: These are MAOIs; check serotonergic drug list
6. Communication: Ensure all prescribers aware of serotonergic medications

---

SAQ Practice Questions

SAQ 1: Drug Interaction Causing Serotonin Syndrome

Stem:

A 52-year-old woman is brought to the Emergency Department by ambulance with agitation, confusion, and tremor. She has a history of treatment-resistant depression and chronic pain. Her current medications include:

• Tranylcypromine 30 mg daily (started 3 months ago)
• Paracetamol 1 g QID
• Pregabalin 150 mg BD

Her daughter reports that 8 hours ago, her mother was given tramadol 50 mg by a locum GP for an acute exacerbation of back pain.

On examination:

• Temperature 39.8 degrees Celsius
• HR 128 bpm, BP 165/95 mmHg
• GCS 14 (E4V4M6)
• Dilated pupils bilaterally
• Profuse diaphoresis
• Marked lower limb hyperreflexia with 5 beats of clonus at both ankles
• Tremor of outstretched hands

Questions:

(a) What is the most likely diagnosis? Justify your answer with reference to the clinical findings. (4 marks)

(b) Explain the mechanism by which the drug interaction caused this syndrome. (4 marks)

(c) Outline your immediate management priorities. (6 marks)

(d) What specific antidote would you administer? Provide the dosing regimen. (3 marks)

(e) What factors would prompt you to consider intubation and paralysis? (3 marks)

---

SAQ 1: Model Answer

(a) Diagnosis and Justification (4 marks)

Diagnosis: Serotonin Syndrome

Clinical justification using Hunter Serotonin Toxicity Criteria:

1. Serotonergic agent exposure: Yes - Tranylcypromine (MAOI) + Tramadol (SERT inhibitor)
2. Clinical features meeting criteria:
   • Inducible clonus (5 beats at ankles) PLUS
   • Agitation (confused, GCS 14) PLUS
   • Diaphoresis (profuse sweating)

Additional supportive features:

• Hyperthermia (39.8 degrees Celsius)
• Tachycardia (128 bpm)
• Hypertension (165/95 mmHg)
• Mydriasis (dilated pupils)
• Hyperreflexia
• Tremor
• Rapid onset (8 hours after tramadol)

(b) Mechanism of Drug Interaction (4 marks)

Tranylcypromine is an irreversible, non-selective monoamine oxidase inhibitor (MAOI):

• Inhibits MAO-A and MAO-B enzymes
• Prevents degradation of serotonin (5-HT) in presynaptic terminals and synaptic cleft
• Results in accumulation of 5-HT in CNS

Tramadol is a serotonin reuptake transporter (SERT) inhibitor:

• Blocks reuptake of serotonin from synaptic cleft back into presynaptic neuron
• Also causes weak 5-HT release

Combined effect:

• MAO inhibition → ↓ serotonin breakdown → ↑ presynaptic 5-HT stores
• SERT inhibition → ↓ reuptake from synaptic cleft
• Net result: Massive excess of serotonin at postsynaptic receptors (especially 5-HT2A)
• 5-HT2A activation causes neuromuscular excitation (clonus, hyperreflexia), hyperthermia, and autonomic instability

This is a contraindicated combination - Tramadol is absolutely contraindicated within 2-3 weeks of MAOI use.

(c) Immediate Management Priorities (6 marks)

1. Cease all serotonergic agents:

• Stop tramadol and tranylcypromine immediately
• Review all medications for serotonergic potential

2. Supportive care:

• IV access (large-bore, 2 sites)
• Continuous cardiac monitoring
• Continuous core temperature monitoring
• IV crystalloid resuscitation (for rhabdomyolysis prevention and hyperthermia)

3. Benzodiazepines:

• Diazepam 5-10 mg IV OR Midazolam 5 mg IV
• Repeat every 10-15 minutes as needed
• Controls agitation, reduces muscle hyperactivity, decreases heat generation

4. Active cooling:

• Evaporative cooling (lukewarm water spray + fans)
• Ice packs to axillae, groin, neck
• Target core temperature less than 39 degrees Celsius

5. Investigations:

• ABG (acidosis assessment)
• CK (rhabdomyolysis)
• UEC (renal function, electrolytes)
• Coagulation (DIC)
• Paracetamol level (co-ingestion screen)

6. Disposition:

• ICU admission for close monitoring
• Toxicology consultation

(d) Specific Antidote and Dosing (3 marks)

Cyproheptadine (5-HT2A receptor antagonist)

Dosing regimen:

• Loading dose: 12 mg orally or via nasogastric tube immediately
• Maintenance dose: 2 mg every 2 hours until symptoms improve
• Alternative maintenance: 4-8 mg every 6 hours once stable
• Maximum daily dose: 32 mg

(e) Indications for Intubation and Paralysis (3 marks)

• Core temperature greater than 41.1 degrees Celsius (life-threatening hyperthermia)
• Refractory hyperthermia despite benzodiazepines, cyproheptadine, and active cooling
• Severe muscle rigidity preventing adequate ventilation
• Severe agitation not controlled by benzodiazepines
• Airway protection if GCS significantly impaired (less than 8)
• Respiratory failure or ARDS
• Ongoing rhabdomyolysis (CK continuing to rise) despite treatment

Important: Use non-depolarising agents (rocuronium); AVOID suxamethonium (hyperkalaemia risk from rhabdomyolysis)

---

SAQ 2: Serotonin Syndrome vs Neuroleptic Malignant Syndrome

Stem:

A 35-year-old man with schizophrenia is referred from a psychiatric unit with fever, altered mental status, and muscular rigidity. He was commenced on haloperidol depot 100 mg IM 5 days ago for treatment of an acute psychotic episode. Background medications include sertraline 100 mg daily (unchanged for 2 years).

On examination:

• Temperature 40.2 degrees Celsius
• HR 115 bpm, BP 150/90 mmHg
• GCS 12 (E3V4M5)
• Generalised muscular rigidity ("lead-pipe" quality)
• Reflexes difficult to elicit due to rigidity
• No clonus
• Pupils 4 mm bilaterally, equal and reactive
• Decreased bowel sounds
• Skin warm and diaphoretic

Questions:

(a) What are the two main differential diagnoses? (2 marks)

(b) In a table format, outline at least 6 clinical features that help distinguish between these two conditions. (6 marks)

(c) Based on the clinical features provided, which diagnosis is most likely? Justify your answer. (4 marks)

(d) Outline the specific management for each of these two conditions. (6 marks)

(e) What investigation would be most useful in prognostication for the likely diagnosis? (2 marks)

---

SAQ 2: Model Answer

(a) Two Main Differential Diagnoses (2 marks)

1. Neuroleptic Malignant Syndrome (NMS)
2. Serotonin Syndrome

(b) Distinguishing Clinical Features Table (6 marks)

(c) Most Likely Diagnosis and Justification (4 marks)

Most Likely Diagnosis: Neuroleptic Malignant Syndrome (NMS)

Justification:

While the patient is also on sertraline, the clinical features strongly favour NMS:

• Absence of clonus is the single most important differentiating feature
• Lead-pipe rigidity without clonus points to NMS
• Slow onset (5 days) consistent with NMS, not SS

(d) Specific Management for Each Condition (6 marks)

Neuroleptic Malignant Syndrome Management:

1. Stop causative agent: Cease haloperidol (and all dopamine antagonists)
2. Supportive care: IV fluids, active cooling, ICU monitoring
3. Specific treatment:
   • Bromocriptine 2.5-5 mg PO/NG every 8 hours (dopamine agonist)
   • OR Amantadine 100-200 mg PO every 12 hours
   • Dantrolene 1-2.5 mg/kg IV (muscle relaxant) for severe rigidity/hyperthermia
4. Benzodiazepines for agitation
5. Monitor CK (rhabdomyolysis risk high)
6. ECT may be considered if refractory

Serotonin Syndrome Management:

1. Stop causative agent: Cease all serotonergic drugs
2. Supportive care: IV fluids, active cooling, ICU monitoring
3. Benzodiazepines: First-line for agitation and muscle hyperactivity
4. Cyproheptadine: 12 mg loading, then 2 mg every 2 hours (5-HT2A antagonist)
5. Paralysis if severe: Rocuronium (avoid suxamethonium)
6. Active cooling for hyperthermia

Key Difference: Bromocriptine/dantrolene for NMS; Cyproheptadine for SS

(e) Investigation for Prognostication (2 marks)

Creatine Kinase (CK)

• CK greater than 10,000 U/L indicates severe NMS with significant rhabdomyolysis
• Higher CK levels correlate with:
  • Increased risk of AKI
  • Longer duration of illness
  • Higher mortality
• Serial CK monitoring useful for tracking disease progression/resolution

---

Viva Scenarios

Viva Scenario 1: Serotonin Syndrome Clinical Presentation

Examiner: "A 28-year-old woman is brought to your Emergency Department having been found confused and agitated by her housemates. She has a background of depression and takes escitalopram. Her housemates found empty blister packs of her antidepressant and an unknown supplement bottle. On arrival she is febrile (39.5 degrees Celsius), tachycardic (130 bpm), and diaphoretic with dilated pupils. She is tremulous with brisk reflexes."

Opening Question: "What is your differential diagnosis and what examination findings would you specifically look for?"

---

Candidate: "Thank you. This clinical presentation suggests a hyperthermic toxidrome in a patient taking an SSRI with possible polypharmacy. My differential diagnoses would be:

Primary considerations:

1. Serotonin syndrome - most likely given SSRI use, rapid onset, autonomic features
2. Anticholinergic toxidrome - if the supplement contains anticholinergic agents
3. Sympathomimetic toxidrome - if amphetamine/stimulant co-ingestion

Other considerations: 4. Neuroleptic malignant syndrome - less likely without antipsychotic use 5. Sepsis/meningitis - must exclude 6. Thyroid storm

Key examination findings I would specifically look for to differentiate:

For serotonin syndrome:

• Clonus - spontaneous, inducible at ankles, or ocular clonus (most important)
• Hyperreflexia
• Myoclonus
• Diaphoresis (WET skin)
• Hyperactive bowel sounds

For anticholinergic toxidrome:

• DRY skin and mucous membranes
• Urinary retention
• Absent bowel sounds
• Mydriasis (more marked than SS)
• NO clonus

For sympathomimetic:

• Similar autonomic features but NO clonus
• May have chest pain, palpitations"

---

Examiner: "You examine her and find sustained clonus at both ankles (greater than 5 beats) and hyperreflexia throughout. Her skin is wet with perspiration and bowel sounds are normal. What is your diagnosis and what diagnostic criteria would you apply?"

---

Candidate: "Based on these findings, my diagnosis is serotonin syndrome.

I would apply the Hunter Serotonin Toxicity Criteria, which require:

1. Serotonergic agent exposure: Yes - escitalopram (SSRI) plus unknown supplement (possibly serotonergic such as St John's wort or 5-HTP)

2. Clinical criteria met: She has inducible clonus (greater than 5 beats sustained) PLUS agitation (confused and agitated) PLUS diaphoresis (diaphoretic)

This satisfies the Hunter criteria. The additional supportive features include:

• Hyperthermia (39.5 degrees Celsius)
• Tachycardia (130 bpm)
• Mydriasis
• Hyperreflexia
• Tremor

The Hunter criteria have sensitivity of 84% and specificity of 97% for moderate-to-severe serotonin syndrome. The presence of clonus is the key distinguishing feature from other hyperthermic syndromes."

---

Examiner: "Tell me about the pathophysiology. Which receptors are involved?"

---

Candidate: "Serotonin syndrome results from excess serotonergic activity at central nervous system synapses. The key points of pathophysiology are:

Serotonin receptors involved:

The 5-HT2A receptor is the primary mediator of serotonin syndrome toxicity:

• Located on cortical neurons, brainstem, and spinal cord interneurons
• Gq-coupled excitatory receptor
• Activation causes: hyperthermia, myoclonus, clonus, agitation
• This is the target of cyproheptadine (antagonist)

The 5-HT1A receptor also contributes:

• Gi-coupled inhibitory receptor
• Located in raphe nuclei and limbic system
• Contributes to autonomic effects

Mechanisms of increased synaptic serotonin:

In this patient with SSRI plus supplement:

1. Escitalopram blocks the serotonin reuptake transporter (SERT), preventing clearance of serotonin from the synaptic cleft

2. If the supplement is St John's wort or 5-HTP:

   • St John's wort has SERT inhibition plus weak MAO inhibition
   • 5-HTP is a direct serotonin precursor, increasing synthesis

The net result is excess 5-HT at postsynaptic receptors, particularly 5-HT2A, causing the clinical syndrome.

Hyperthermia mechanisms:

• Central thermoregulatory failure (hypothalamic 5-HT2A)
• Muscle hyperactivity generating metabolic heat
• Impaired heat dissipation from vasoconstriction"

---

Examiner: "What is your management plan?"

---

Candidate: "My management follows a systematic approach:

Immediate priorities:

1. Cease all serotonergic agents - stop escitalopram, identify and stop supplement

2. Supportive care:

   • IV access, continuous cardiac monitoring
   • Core temperature monitoring
   • IV crystalloid resuscitation

3. Benzodiazepines - first-line for agitation and muscle hyperactivity:

   • Diazepam 5-10 mg IV OR Midazolam 5 mg IV
   • Repeat every 10-15 minutes as needed
   • This reduces heat generation and controls agitation

4. Active cooling for temperature greater than 39.5 degrees Celsius:

   • Evaporative cooling (spray and fans)
   • Ice packs to axillae, groin
   • Target less than 39 degrees Celsius
   • Antipyretics are NOT effective

5. Cyproheptadine - specific 5-HT2A antagonist:

   • Loading dose: 12 mg orally or via NG tube
   • Maintenance: 2 mg every 2 hours
   • Maximum: 32 mg per day

6. Investigations:

   • CK for rhabdomyolysis
   • ABG for acidosis
   • UEC for renal function
   • Paracetamol level to exclude co-ingestion
   • Consider identifying the supplement

7. Disposition:

   • ICU admission for monitoring
   • Toxicology consultation

If she deteriorates with temperature greater than 41 degrees Celsius or refractory to above:

• Intubation with rocuronium (avoid suxamethonium)
• Paralysis eliminates muscle-generated heat
• Continue cyproheptadine and benzodiazepines for sedation"

---

Examiner: "Why do you avoid suxamethonium?"

---

Candidate: "Suxamethonium is contraindicated in serotonin syndrome for two reasons:

1. Hyperkalaemia risk: Patients with serotonin syndrome often have rhabdomyolysis from sustained muscle hyperactivity. Rhabdomyolysis causes muscle membrane instability and upregulation of extrajunctional acetylcholine receptors. Suxamethonium depolarises these receptors, causing massive potassium efflux that can lead to life-threatening hyperkalaemia and cardiac arrest.

2. Muscle rigidity pattern: Suxamethonium can cause transient rigidity which may worsen hyperthermia and confuse the clinical picture.

I would use rocuronium 1-1.2 mg/kg as it is a non-depolarising agent that does not cause potassium release. Sugammadex is available for reversal if needed.

The same principle applies to any patient with suspected rhabdomyolysis, burns, prolonged immobilisation, denervation injuries, or crush injuries."

---

Viva Scenario 2: MAOI Drug Interaction

Examiner: "You are called to the ward to review a 62-year-old man who developed confusion and tremor 4 hours after a procedure. He is 2 days post-coronary artery bypass graft. His background includes treatment-resistant depression managed with tranylcypromine. You note in the anaesthetic chart that he received intraoperative methylene blue for vasoplegic syndrome."

Opening Question: "What do you think has happened and why?"

---

Candidate: "Thank you. This presentation strongly suggests serotonin syndrome caused by the interaction between tranylcypromine and methylene blue.

Tranylcypromine is an irreversible, non-selective monoamine oxidase inhibitor (MAOI). It inhibits both MAO-A and MAO-B, preventing the degradation of serotonin in the CNS.

Methylene blue is often overlooked as having MAOI properties:

• It is a potent, reversible MAO-A inhibitor (Ki approximately 27 nM)
• When administered IV at doses greater than 1 mg/kg, it achieves concentrations sufficient to inhibit MAO-A
• This was recognised in FDA warnings in 2011 after reports of serotonin syndrome

Mechanism of interaction: The patient already has inhibited MAO from tranylcypromine. Adding methylene blue provides additional MAO-A inhibition, leading to massive accumulation of serotonin in the CNS.

This is a well-documented drug interaction and methylene blue is now contraindicated in patients taking serotonergic medications, particularly MAOIs.

The timing is appropriate - onset 4 hours after methylene blue administration is consistent with serotonin syndrome's typical 6-24 hour onset."

---

Examiner: "How would you confirm this diagnosis?"

---

Candidate: "Serotonin syndrome is a clinical diagnosis. There is no confirmatory blood test. I would apply the Hunter Serotonin Toxicity Criteria:

Step 1: Confirm serotonergic exposure

• Yes: Tranylcypromine (MAOI) plus methylene blue (MAO-A inhibitor)

Step 2: Examine for specific clinical features

I would specifically examine for:

• Clonus: Spontaneous, inducible (ankle dorsiflexion), or ocular (slow horizontal eye movements)
• Hyperreflexia: Brisk deep tendon reflexes
• Tremor: Fine tremor of outstretched hands
• Muscle rigidity: Increased tone, especially lower limbs
• Autonomic features: Temperature, diaphoresis, mydriasis, tachycardia, blood pressure
• Mental status: Agitation, confusion level

If he has clonus (any type) with agitation or diaphoresis, or tremor plus hyperreflexia plus clonus, this confirms serotonin syndrome by Hunter criteria.

Investigations to assess severity:

• CK for rhabdomyolysis
• ABG for metabolic acidosis
• Core temperature (may be elevated despite post-surgical setting)
• ECG for arrhythmias

Important to exclude:

• Post-operative sepsis
• Stroke or intracranial event
• Other post-CABG complications
• NMS is unlikely as there's no dopamine antagonist exposure"

---

Examiner: "You examine him. He has a temperature of 38.8 degrees Celsius, HR 118, and you find ocular clonus and marked diaphoresis. His lower limb reflexes are brisk with 3 beats of ankle clonus. He is confused but rousable. How do you manage this?"

---

Candidate: "This confirms moderate serotonin syndrome by Hunter criteria: ocular clonus plus diaphoresis.

Immediate management:

1. Cease serotonergic agents:

   • Methylene blue was a single dose - already administered
   • Tranylcypromine - hold doses
   • Review all medications for serotonergic properties
   • Note: MAO inhibition from tranylcypromine is irreversible and will persist for 2-3 weeks until new enzyme synthesised

2. Notify surgical team - This patient requires close monitoring in a high-acuity setting, potentially ICU

3. Benzodiazepines:

   • Diazepam 5 mg IV, repeat every 15 minutes as needed
   • Controls agitation and reduces muscle hyperactivity

4. Cyproheptadine:

   • 12 mg via NG tube as loading dose
   • 2 mg every 2 hours maintenance
   • He may have an NG tube from surgery; if not, oral or NG insertion

5. Supportive care:

   • IV fluids for hydration and rhabdomyolysis prevention
   • Active cooling if temperature rises (currently 38.8 degrees Celsius - monitor closely)
   • Continuous cardiac monitoring (important post-CABG)

6. Investigations:

   • CK, troponin, ABG, UEC, coagulation
   • Consider ECG to assess for arrhythmias

7. Special considerations for post-CABG patient:

   • Cardiothoracic surgery team involvement
   • May have sternal precautions limiting some cooling techniques
   • Bleeding risk if coagulopathy develops
   • Haemodynamic instability may be multifactorial

8. Communication:

   • Incident report regarding drug interaction
   • Pharmacy review
   • Document in medication allergies: 'Serotonin syndrome with methylene blue - on MAOI'"

---

Examiner: "His temperature rises to 40.5 degrees Celsius over the next 2 hours despite benzodiazepines and cyproheptadine. What now?"

---

Candidate: "This is now severe serotonin syndrome with life-threatening hyperthermia. He requires immediate escalation:

1. Prepare for intubation and paralysis:

• This is now indicated given temperature greater than 41 degrees Celsius threshold approaching
• Paralysis eliminates muscle-generated heat
• Pre-oxygenate thoroughly

2. Induction agents:

• Ketamine or propofol for induction
• Avoid if possible any further cardiac compromise

3. Neuromuscular blockade:

• Rocuronium 1.2 mg/kg (rapid onset, non-depolarising)
• AVOID suxamethonium - he likely has early rhabdomyolysis; risk of severe hyperkalaemia

4. Aggressive active cooling:

• Evaporative cooling with fans
• Ice packs to axillae, groin, neck (mindful of sternal wound)
• Cold IV saline 30 mL/kg (monitor fluid balance post-CABG)
• Consider intravascular cooling catheter if available
• Target: Temperature less than 39 degrees Celsius

5. Continue pharmacotherapy:

• Continue cyproheptadine via NG (even paralysed, still beneficial)
• Propofol infusion for sedation
• Benzodiazepines as adjunct

6. Monitor for complications:

• CK trending (rhabdomyolysis)
• Urine output (AKI prevention - target greater than 1-2 mL/kg/hr)
• Coagulation (DIC screen)
• ABG (metabolic acidosis)

7. Special post-CABG considerations:

• Discuss with cardiothoracic surgery
• Monitor for arrhythmias on paralysed patient
• Maintain adequate perfusion pressure for grafts
• Consider need for inotropic support

8. Duration:

• Continue paralysis until temperature controlled
• May need 24-48 hours given irreversible MAOI
• Wean paralysis when temperature stable less than 38.5 degrees Celsius for 6-12 hours

Prognosis: Despite severity, prognosis remains reasonable if treated aggressively. However, MAOI involvement may prolong course. The combination with post-cardiac surgery is concerning for complications."

---

---

References

1. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. PMID: 15784664

2. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361-365. PMID: 17874986

3. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100-109. PMID: 10221364

4. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7(5):587-596. PMID: 18759711

5. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28(5):205-214. PMID: 16239759

6. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79(4):201-209. PMID: 10941349

7. Isbister GK. Serotonin syndrome: how to avoid, identify, & treat dangerous drug interactions. Current Psychiatry. 2010;9(6):35-47.

8. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. PMID: 12925718

9. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ. 2003;168(11):1439-1442. PMID: 12771076

10. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-441. PMID: 16051647

11. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. PMID: 2035713

12. Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care. 2014;21(1):108-113. PMID: 24052457

13. Gnanadesigan N, Espinoza RT, Smith R, et al. Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc. 2005;6(4):265-269. PMID: 16005413

14. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615-619. PMID: 9696181

15. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994;331(15):1021-1022. PMID: 8084357

16. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45(2):219-223. PMID: 7854515

17. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther. 2008;31(3):187-199. PMID: 18471139

18. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366. PMID: 19630576

19. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083-1152. PMID: 10462127

20. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71(4):533-554. PMID: 11888546

21. Nisijima K, Shioda K, Iwamura T. Neuroleptic malignant syndrome and serotonin syndrome. Prog Brain Res. 2007;162:81-104. PMID: 17645916

22. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277-285. PMID: 15362595

23. Rusyniak DE, Sprague JE. Hyperthermic syndromes induced by toxins. Clin Lab Med. 2006;26(1):165-184. PMID: 16567230

24. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. 2000;18(2):317-325. PMID: 10767886

25. Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359-388. PMID: 22407614

26. Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry. 2007;164(7):1044-1049. PMID: 17606656

27. Roth BL, Driscol J. PDSP Ki Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the US National Institute of Mental Health.

28. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533-540. PMID: 24358002

29. Gillman PK. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord. 2010;25(12):1780-1790. PMID: 20623809

30. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24(2):155-162. PMID: 22563571

31. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626. PMID: 24554467

32. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995;13(2):94-104. PMID: 7576268

33. Nisijima K, Yoshino T, Yui K, Katoh S. Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001;890(1):23-31. PMID: 11164765

34. Kapur S, Zipursky RB, Jones C, et al. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry. 1997;154(6):884. PMID: 9167530

35. Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104(1):158-169. PMID: 16394702

36. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62-72. PMID: 19571284

37. Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135. PMID: 27301374

38. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. PMID: 10739407

39. Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364-373. PMID: 15023108

40. Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21. PMID: 17456235

41. Australian and New Zealand Intensive Care Society (ANZICS). ANZICS Position Statement on End-of-Life Care. Melbourne: ANZICS; 2023.

42. Therapeutic Guidelines. eTG Complete. Melbourne: Therapeutic Guidelines Limited; 2024.

43. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework 2023 Report. Canberra: AIHW; 2023.

44. Royal Flying Doctor Service. Clinical Protocols Manual. Sydney: RFDS; 2024.

45. Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. BMC Neurol. 2016;16:97. PMID: 27342765

46. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13(4):763-783. PMID: 9330840

47. Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician. 2010;81(9):1139-1142. PMID: 20433130

48. Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol (Phila). 2008;46(8):771-773. PMID: 18803091

---

Related Topics

• Neuroleptic Malignant Syndrome
• Anticholinergic Toxidrome
• Tricyclic Antidepressant Overdose
• Opioid Overdose
• MDMA/Amphetamine Toxicity
• Hyperthermia Management
• Rhabdomyolysis
• Thermoregulation Physiology
• Neurotransmitter Pharmacology